{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:26:52Z","timestamp":1787758012377,"version":"build-2784847793"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>In this double-blind, randomized clinical trial, the effectiveness of buprenorphine (BUPRE) in the reduction of anxiety symptoms among the methamphetamine (MA) dependents was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      The 60 MA-dependent patients were randomly assigned to three groups (0.1 mg, 1 mg, and 8 mg of BUPRE), The Hamilton Anxiety Rating Scale was administrated to assess the anxiety symptoms daily at baseline and second to the 5\n                      <jats:sup>th<\/jats:sup>\n                      day after intervention. The inclusion criteria were the MA dependence, age of over 18 years, and absence of any chronic physical illnesses; exclusion criteria were the presence of other drug dependence in combination with MA. The mixed-design analysis of variance was performed for data analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A significant main effect of time (\n                      <jats:italic toggle=\"yes\">F<\/jats:italic>\n                      = 51.456,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and group (\n                      <jats:italic toggle=\"yes\">F<\/jats:italic>\n                      = 4.572,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.014) and group-by-time interaction (\n                      <jats:italic toggle=\"yes\">F<\/jats:italic>\n                      = 8.475,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) were detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This finding supports the efficacy of BUPRE to decrease anxiety. High doses of the drug (1 and 8 mg) were more effective than 0.1 mg. Here was not a significant difference between anxiety score when patients received 1 mg of BUPRE instead of 8 mg.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tcmj.tcmj_297_21","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T02:49:17Z","timestamp":1655174957000},"page":"89-94","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Anxiety treatment of methamphetamine-dependent patients with buprenorphine: A randomized, double-blind, clinical trial"],"prefix":"10.4103","volume":"35","author":[{"given":"Jamshid","family":"Ahmadi","sequence":"first","affiliation":[{"name":"Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Bazrafshan","sequence":"additional","affiliation":[{"name":"Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Sahraian","sequence":"additional","affiliation":[{"name":"Research Center of Psychiatry and Behavioral Sciences, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Jalali","sequence":"additional","affiliation":[{"name":"Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maedeh","family":"Fakhermanesh","sequence":"additional","affiliation":[{"name":"Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Hooshyari","sequence":"additional","affiliation":[{"name":"Psychiatry and Psychology Research Center, Tehran University of Medical Science, Tehran, Iran"},{"name":"Virtual School of Medical Education and Management, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.npp.1301481","article-title":"Bupropion for the treatment of methamphetamine dependence","volume":"33","author":"Elkashef","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R2-20240828","first-page":"10","article-title":"The prevalence of methamphetamine dependence among Iranian women in methadone maintenance therapy in Tehran, Iran","volume":"13","author":"Massah","year":"2018","journal-title":"Iran J Psychiatry"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajp.2015.05.036","article-title":"Methamphetamine use and treatment in Iran: A systematic review from the most populated Persian Gulf country","volume":"16","author":"Alam-mehrjerdi","year":"2015","journal-title":"Asian J Psychiatr"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1196\/annals.1316.035","article-title":"Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis","volume":"1025","author":"Ujike","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1176\/jnp.12.4.480","article-title":"Psychiatric comorbidity of methamphetamine dependence in a forensic sample","volume":"12","author":"Kalechstein","year":"2000","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1355617704101021","article-title":"Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons","volume":"10","author":"Rippeth","year":"2004","journal-title":"J Int Neuropsychol Soc"},{"key":"R7-20240828","first-page":"301","article-title":"The need for speed: An update on methamphetamine addiction","volume":"31","author":"Barr","year":"2006","journal-title":"J Psychiatry Neurosci"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.psychres.2010.09.014","article-title":"Psychiatric comorbidity in methamphetamine dependence","volume":"186","author":"Salo","year":"2011","journal-title":"Psychiatry Res"},{"issue":"Suppl 1","key":"R9-20240828","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/02791072.2003.10400511","article-title":"Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment","volume":"35","author":"Shoptaw","year":"2003","journal-title":"J Psychoactive Drugs"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11011-014-9496-5","article-title":"Psychiatric disorders in individuals with methamphetamine dependence: Prevalence and risk factors","volume":"29","author":"Akindipe","year":"2014","journal-title":"Metab Brain Dis"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.drugalcdep.2016.10.001","article-title":"Barriers to accessing methamphetamine treatment: A systematic review and meta-analysis","volume":"168","author":"Cumming","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1521-0391.2010.00061.x","article-title":"Anxiety disorders among methamphetamine dependent adults: Association with post-treatment functioning","volume":"19","author":"Glasner-Edwards","year":"2010","journal-title":"Am J Addict"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/ajad.12644","article-title":"The impact of mental health comorbidities on adherence to buprenorphine: A claims based analysis","volume":"26","author":"Litz","year":"2017","journal-title":"Am J Addict"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1521-0391.2013.12074.x","article-title":"Predictive factors for relapse in patients on buprenorphine maintenance","volume":"23","author":"Ferri","year":"2014","journal-title":"Am J Addict"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.v67n0211","article-title":"Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"67","author":"Conway","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drugalcdep.2012.05.025","article-title":"Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine","volume":"126","author":"Lofwall","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.drugalcdep.2008.03.010","article-title":"Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence","volume":"96","author":"Shoptaw","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/JCP.0000000000000408","article-title":"The effect of buprenorphine on methamphetamine cravings","volume":"35","author":"Salehi","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/02791072.2010.10400689","article-title":"Buprenorphine in the treatment of opiate dependence","volume":"42","author":"Wesson","year":"2010","journal-title":"J Psychoactive Drugs"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1345\/aph.10421","article-title":"Opioid dependence treatment, including buprenorphine\/naloxone","volume":"36","author":"Raisch","year":"2002","journal-title":"Ann Pharmacother"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/10550490701860971","article-title":"Long-term treatment with buprenorphine\/naloxone in primary care: Results at 2-5 years","volume":"17","author":"Fiellin","year":"2008","journal-title":"Am J Addict"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: Assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatr Serv"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13063-017-2007-3","article-title":"Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: A randomized clinical trial","volume":"18","author":"Ahmadi","year":"2017","journal-title":"Trials"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.1982.tb39483.x","article-title":"Possible antidepressive effects of opioids: Action of buprenorphine","volume":"398","author":"Emrich","year":"1982","journal-title":"Ann N Y Acad Sci"},{"key":"R25-20240828","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1744-859X-10-17","article-title":"Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?","volume":"10","author":"Maremmani","year":"2011","journal-title":"Ann Gen Psychiatry"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.clpt.6100503","article-title":"Potential of buprenorphine\/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders","volume":"83","author":"McCann","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4103\/0253-7176.211765","article-title":"Anxiety treatment of opioid dependent patients with buprenorphine: A randomized, double-blind, clinical trial","volume":"39","author":"Ahmadi","year":"2017","journal-title":"Indian J Psychol Med"},{"key":"R28-20240828","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.psyneuen.2015.09.011","article-title":"Effects of buprenorphine on responses to social stimuli in healthy adults","volume":"63","author":"Bershad","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"R29-20240828","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamapsychiatry.2018.3537","article-title":"Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: A randomized clinical trial and follow-up study","volume":"76","author":"Latif","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"R30-20240828","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"R31-20240828","first-page":"1","article-title":"Structured clinical interview for the DSM (SCID)","author":"First","year":"2014","journal-title":"The encyclopedia of clinical psychology. Online Willy Library"},{"key":"R32-20240828","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"R33-20240828","doi-asserted-by":"crossref","first-page":"e6434","DOI":"10.1097\/MD.0000000000006434","article-title":"Anxiety level and correlates in methamphetamine-dependent patients during acute withdrawal","volume":"96","author":"Su","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R34-20240828","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsat.2016.08.011","article-title":"A review of methamphetamine dependence and withdrawal treatment: A focus on anxiety outcomes","volume":"71","author":"Hellem","year":"2016","journal-title":"J Subst Abuse Treat"},{"key":"R35-20240828","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00213-014-3723-y","article-title":"Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice","volume":"232","author":"Falcon","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"R36-20240828","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1515\/ijamh-2013-0069","article-title":"Buprenorphine in the treatment of non-suicidal self-injury: A case series and discussion of the literature","volume":"25","author":"Norelli","year":"2013","journal-title":"Int J Adolesc Med Health"},{"key":"R37-20240828","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ijnp\/pyx077","article-title":"Effects of Buprenorphine on Responses to Emotional Stimuli in Individuals with a Range of Mood Symptomatology","volume":"21","author":"Bershad","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"R38-20240828","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.4088\/JCP.13m08725","article-title":"Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults","volume":"75","author":"Karp","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"R39-20240828","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","article-title":"Buprenorphine treatment of refractory depression","volume":"15","author":"Bodkin","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"R40-20240828","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","article-title":"Buprenorphine pharmacology review: Update on transmucosal and long-acting formulations","volume":"13","author":"Coe","year":"2019","journal-title":"J Addict Med"},{"key":"R41-20240828","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pnpbp.2015.01.001","article-title":"Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment","volume":"62","author":"Crowley","year":"2015","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R42-20240828","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.psyneuen.2014.12.004","article-title":"Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans","volume":"52","author":"Bershad","year":"2015","journal-title":"Psychoneuroendocrinology"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_297_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:00:45Z","timestamp":1787756445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_297_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_297_21","relation":{},"ISSN":["1016-3190","2223-8956"],"issn-type":[{"value":"1016-3190","type":"print"},{"value":"2223-8956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]},"assertion":[{"value":"2021-11-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}